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Figure 1. Kinetic Resolution of Racemic Solketal Acetate with O.16
Esterase Proceeded with the Highest Enantioselectivity Reported
So Far in the Literature
level of structural and functional complexity than other
known esterases.
In conclusion, the work by Ferrer and coworkers
does not only add new enzymes to the number of avail-
able biocatalysts. It substantially expands our knowl-
edge about enzyme functions and exemplifies Nature’s
ability to evolve remarkable biocatalysts with no sim-
ilarity to known enzymes and bearing striking biochem-
ical properties, which would have been rather impos-
sible to discover without the metagenome approach.
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In this issue of Chemistry & Biology, Li and Lawrence
[1] report an iterative synthesis/selection process to
identify chemically modified peptide ligands possess-
ing high affinity and selectivity for the SH3 domain of
Fyn, a member of the Src kinase family.
Protein-protein interactions within families of highly re-
lated macromolecular structures have proven to be
among the most challenging assignments for develop-
ment of suitable pharmacologic reagents. Associations
between flat, complementary surfaces which are char-
acteristic of protein-protein interactions involve discon-
tinuous protein epitopes whose binding determinants
are difficult to interrupt or mimic with small molecules.
High-throughput screening (HTS) of small-molecule li-
braries has also proven to be largely unsuccessful, pre-
sumably because most compound collections tend to
be structurally biased to conventional targets such G
protein-coupled receptors and kinases. Furthermore,
this approach is subject to a higher-than-usual occur-
rence of artifacts and other false positives [2].
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ions that modulate the activity of Src tyrosine kinases
n both normal and disease states [3]. These findings
ave heightened the level of interest in the functional
nd mechanistic aspects of SH3 signaling and in-
reased the potential medicinal value of selective mod-
lators in SH3-mediated pathology [4, 5]. Chemically
ased inhibitors, unlike genetic knockouts, lend them-
elves to dose-dependent investigation of SH3 targets
cross a broad spectrum of in vitro and in vivo pharma-
ology. However, high-affinity small-molecule reagents
hat selectively bind SH3 domains have been difficult
o obtain [6, 7], and a general strategy for their acquisi-
ion has yet to emerge. The relatively small binding face
f a representative SH3 binding domain combined with
he appreciable homology among related structures
enders this target class a sizable challenge to conven-
ional optimization technology. Additionally, the tran-
ient SH3 binding complex offers few clues to guide
ntelligent design. Consequently, the majority of re-
orted SH3 peptide ligands bind with micromolar affin-
ty and poor selectivity [8].
Within the Src family kinases, Fyn and the closely re-
ated Lck have been shown to play a key role in initia-
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861tion of signaling through the T cell antigen receptor [9].
While the function of Lck in mediating T cell develop-
ment and differentiation has been clearly defined using
Lck-deficient cell lines, the importance of Fyn is less
well understood. Recent evidence, however, indicates
that Fyn is critical to the activation and proliferation of
naive T cells [10], making this protein an attractive tar-
get for pharmacological control.
While no diversity- or knowledge-based approach
has successfully emerged for targeting SH3 com-
plexes, approaches derived from the study of other dif-
ficult targets have been applied to SH3 domains. Two
of these reports utilize structure-based fragment selec-
tion guided by either NMR [11] or X-ray crystallography
[12] to generate libraries of weak binding fragments.
Such fragments are then optimized for affinity and se-
lectivity as part of a larger molecular scaffold or by iter-
ative rounds of structural modification. The Li and Law-
rence report [1], unlike these prior approaches, is based
entirely on iterative library construction and deconvo-
lution.
The authors utilized the consensus peptide RALPPLP,
with only micromolar affinity for Fyn and no selectivity
for the related kinases, as a starting point for optimiza-
tion. Introduction of an optimized diversity element
through acylation of the N terminus with a diverse set
of carboxylic acids yielded a derivative with binding af-
finity roughly 10-fold greater than the starting peptide,
but with no apparent selectivity. Amplification of this
lead in the second optimization round by introducing
diversity at the C terminus produced a further improve-
ment in potency as well as a hint of selectivity. In the
last optimization round, which focused upon the sec-
ond amino acid in the peptide (Ala), the authors were
able to identify an even more potent ligand which ex-
hibited approximately a ten-fold selectivity for Fyn over
the other kinases, including Lck. Finally, the authors
were able to demonstrate functional capability of this
novel optimized ligand by disruption of a WASp/Fyn
signaling complex.
The report by Li and Lawrence represents an impor-
tant step forward in the development of methodology
for identification and optimization of reagents for
broad-based pharmacological study. The work high-
lights the unique role chemical reagents serve in the
elucidation of specific macromolecular targets within
biological signaling pathways [2]. The most noteworthy
contribution of this report resides in the systematic ap-
proach by which one of the most vexing problems in
chemical biology, the disruption of protein-protein in-
teractions, is overcome. The stepwise modification of
a consensus peptide with a diverse collection of car-
boxylic acids yielded an appreciably potent and selec-
tive Fyn SH3 inhibitor in a straightforward manner.
To place this work in a historical context, the authors’
reference to “an easily automated methodology” invites
acknowledgment of the cornerstone of this methodol-
ogy. Solid-phase synthesis from its original conceptionby Merrifield [13] to its more recent applications in
chemical biology remains an enabling force in scientific
investigation. This is most apparent in the assignment
of function to structure within the human genome
where the application of genetic deletion or “knockout”
strategies has proven insufficient or equivocal. As a
result, traditional pharmacology represents a reliable
and complementary approach to determining gene
function.
The present work exemplifies the broad and unantici-
pated utility of the tools developed in the context of
combinatorial chemistry [14–17] and subsequently re-
fined in the course of its evolution into diversity-ori-
ented synthesis [18]. The speed and simplicity of these
methods enables a broader segment of the scientific
community to participate in the identification and char-
acterization of functional aspects of the genome.
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